Cumberland Pharma Stock Rises After China Antibiotic Launch — Why Investors Are Watching
Cumberland Pharmaceuticals Inc. shares rose on Friday after the company said its Vibativ antibiotic had launched in China through partner SciClone Pharmaceuticals, giving the small U.S. drugmaker a new overseas commercial trigger a month after it agreed to sell its branded U.S. portfolio to Apotex. Cumberland was last quoted at $6.15, up 21 cents from its previous close, after trading between $5.95 and $6.25. Its market value, or stock-market worth, stood at about $92 million.